Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Claudia Polloni"'
Autor:
Silvia Gentili, Luciano Giuliodori, Massimo Catarini, Claudia Polloni, Patrizia Caraffa, Marino Brunori, Riccardo Centurioni, Francesco Alesiani, Arduino Samori, Maurizio Burattini, Mario Ferranti, Laura Corvatta, Piero Galieni, Paolo Fraticelli, Massimo Offidani, Giuseppe Visani, Pietro Leoni, Nicola Blasi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 12:423-432
Multiple myeloma (MM) therapy should be tailored according to patient characteristics although we do not know which ones to use. By studying the characteristics of 266 real-life patients, we found performance status (PS) and Charlson Comorbidity Inde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08c9234a41dbbd1e8a35b8e367fa71a5
https://doi.org/10.1016/j.clml.2012.06.008
https://doi.org/10.1016/j.clml.2012.06.008
Autor:
Claudia Crippa, Alessandra Romano, Michele Cavo, Francesca Elice, Roberto Marasca, Mario Boccadoro, Massimo Offidani, Renato Zambello, Claudia Cellini, Valeria Magarotto, Vincenzo Callea, Monica Galli, Claudia Polloni, Patrizia Tosi, Angelo Michele Carella, Giulia Benevolo, Elena Zamagni, Andrea Evangelista, Fabiana Gentilini, Stefano Pulini, Antonio Palumbo, Vittorio Montefusco, Sara Bringhen, Chiara Nozzoli, Davide Rossi, Norbert Pescosta, Roberto Ria, Paola Tacchetti, Francesca Patriarca, Luca Baldini, Tommaso Caravita, Fortunato Morabito
Publikováno v:
Journal of Clinical Oncology. 29:986-993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10aaae7aa43cd797d92d93df9cdbdcd9
https://doi.org/10.1200/jco.2010.31.6844
https://doi.org/10.1200/jco.2010.31.6844
Autor:
Rita Rizzi, Annamaria Brioni, Marino Brunori, Giuseppe Visani, Nicola Blasi, Massimo Catarini, Laura Corvatta, Arduino Samori, Paolo Fraticelli, Federica Larocca, Claudia Polloni, Francesco Alesiani, Silvia Gentili, Riccardo Centurioni, Piero Galieni, Mario Ferranti, Massimo Offidani, Pietro Leoni, Anna Mele
Publikováno v:
Leukemia & Lymphoma. 52:776-785
The literature provides scant data concerning infectious complications and their effect on the outcome of patients with multiple myeloma (MM) treated with new drug combinations. Despite no substantial myelotoxic effect, thalidomide increases the risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa1366abfd2de240818470592395d40
https://doi.org/10.3109/10428194.2011.555027
https://doi.org/10.3109/10428194.2011.555027
Autor:
Riccardo Centurioni, Agnese Savini, Laura Corvatta, Marino Brunori, Arduino Samori, Pietro Leoni, Francesco Alesiani, Massimo Catarini, Giuseppe Visani, Piero Galieni, Miriana Ruggieri, Silvia Gentili, Massimo Offidani, Sadia Falcioni, Maurizio Burattini, Paolo Fraticelli, Claudia Polloni, Mauro Montanari
Publikováno v:
European Journal of Haematology. 84:474-483
Objectives: With the aim to address the issue whether high-dose therapy (HDT) is required after new drugs combinations to improve outcome of elderly newly diagnosed multiple myeloma (MM) patients, we compared the toxicity and the outcome of ThaDD plu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::505f4233df005ed1beaebad814627f97
https://doi.org/10.1111/j.1600-0609.2010.01418.x
https://doi.org/10.1111/j.1600-0609.2010.01418.x
Autor:
Marino Brunori, Arduino Samori, Marco Candela, Luciano Giuliodori, Pietro Leoni, Massimo Catarini, Massimo Offidani, Riccardo Centurioni, Laura Corvatta, Anna Mele, Mario Ferranti, Monica Marconi, Piero Galieni, Maurizio Burattini, Maria-Novella Piersantelli, Giuseppe Visani, Silvia Gentili, Claudia Polloni, Francesco Alesiani
Publikováno v:
British Journal of Haematology. 144:653-659
Summary Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD). Patients with newly or relapsed MM obtaining at least minor response after 6 ThaDD c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ba8553e91ef6161941121d471e586a
https://doi.org/10.1111/j.1365-2141.2008.07495.x
https://doi.org/10.1111/j.1365-2141.2008.07495.x
Autor:
Marino Brunori, Luciano Giuliodori, Massimo Catarini, Riccardo Centurioni, Claudia Polloni, Mario Ferranti, Monica Marconi, Maurizio Burattini, Marco Candela, Pietro Leoni, Massimo Offidani, Piero Galieni, Anna Mele, Laura Corvatta, Giuseppe Visani, Francesco Alesiani, Maria-Novella Piersantelli
Publikováno v:
Clinical Lymphoma and Myeloma. 8:294-299
Background Few studies have focused on factors affecting outcome in patients with multiple myeloma (MM) treated with thalidomide-based therapy. We investigated factors affecting response, progression-free survival (PFS), and overall survival (OS) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22aab69025f23cca7b06267be751fae
https://doi.org/10.3816/clm.2008.n.041
https://doi.org/10.3816/clm.2008.n.041
Autor:
Luciano Giuliodori, Marino Brunori, Maria Novella Piersantelli, Piero Galieni, Massimo Offidani, Claudia Polloni, Anna Rita Scortechini, Attilio Olivieri, Serena Rupoli, Massimo Catarini, Antonella Poloni, Debora Capelli, Mario Ferranti, Maurizio Burattini, Pietro Leoni, Francesco Alesiani, Monica Marconi, Riccardo Centurioni, M Montanari, Laura Corvatta, Giuseppe Visani, Marco Candela
Publikováno v:
Blood. 108:2159-2164
We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma. Thalidomide 100 mg was administered ora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f5a32ff026f49de631f9695d0a13b0
https://doi.org/10.1182/blood-2006-03-013086
https://doi.org/10.1182/blood-2006-03-013086
Autor:
Silvia Gentili, Massimo Offidani, Mario Boccadoro, Patrizia Caraffa, Massimo Catarini, Laura Corvatta, Pietro Leoni, Antonio Palumbo, Stelvio Ballanti, Anna Marina Liberati, Federica Cavallo, Francesco Alesiani, Claudia Polloni, Stefano Pulini
Publikováno v:
Leukemialymphoma. 53(9)
The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM). Panobinostat is a potent oral pan-deacetylase inhibitor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b9adef92f225ca0f97803e07976dc2
https://pubmed.ncbi.nlm.nih.gov/22335534
https://pubmed.ncbi.nlm.nih.gov/22335534
Autor:
Patrizia Caraffa, Massimo Catarini, Arduino Samori, Lara Malerba, Silvia Gentili, Claudia Polloni, Nicola Blasi, Anna Mele, Rita Rizzi, Marino Brunori, Pietro Leoni, Massimo Offidani, Laura Corvatta, Mario Ferranti
Publikováno v:
Annals of hematology. 90(12)
In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission. Moreover, there is an emergent body of evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f3f55fec9a023fb7bea111f342abc0b
https://pubmed.ncbi.nlm.nih.gov/21437586
https://pubmed.ncbi.nlm.nih.gov/21437586
Autor:
Massimo, Offidani, Pietro, Leoni, Laura, Corvatta, Claudia, Polloni, Silvia, Gentili, Agnese, Savini, Francesco, Alesiani, Marino, Brunori, Massimo, Catarini, Giuseppe, Visani, Arduino, Samori, Maurizio, Burattini, Riccardo, Centurioni, Mauro, Montanari, Paolo, Fraticelli, Miriana, Ruggieri, Sadia, Falcioni, Piero, Galieni
Publikováno v:
European journal of haematology. 84(6)
With the aim to address the issue whether high-dose therapy (HDT) is required after new drugs combinations to improve outcome of elderly newly diagnosed multiple myeloma (MM) patients, we compared the toxicity and the outcome of ThaDD plus maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3bb9cac3111d87136b5b9e99a17a4936
https://pubmed.ncbi.nlm.nih.gov/20331733
https://pubmed.ncbi.nlm.nih.gov/20331733